Insomnia News and Research RSS Feed - Insomnia News and Research

Insomnia is too little or poor-quality sleep caused by one or more of the following:

Trouble falling asleep
Waking up a lot during the night with trouble returning to sleep
Waking up too early in the morning
Having un-refreshing sleep (not feeling well rested), even after sleeping 7 to 8 hours at night

Insomnia can cause problems during the day, such as excessive sleepiness, fatigue, trouble thinking clearly or staying focused, or feeling depressed or irritable. It is not defined by the number of hours you sleep every night. Although the amount of sleep a person needs varies, most people need between 7 and 8 hours of sleep a night.
Shiftworkers more likely to develop metabolic disorders

Shiftworkers more likely to develop metabolic disorders

Shiftwork is an occupational health risk of growing significance because it is becoming more common and because of its potential influence on health outcomes, possibly increasing health differences between workers of higher vs lower socioeconomic status. [More]
Study finds link between PTSD and accelerated aging

Study finds link between PTSD and accelerated aging

In recent years, public health concerns about post-traumatic stress disorder (PTSD) have risen significantly, driven in part by affected military veterans returning from conflicts in the Middle East and elsewhere. PTSD is associated with number of psychological maladies, among them chronic depression, anger, insomnia, eating disorders and substance abuse. [More]
Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics, Inc. today announced business and financial results for the first quarter ended March 31, 2015. [More]
ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

ViiV Healthcare today announced the start of a Phase III clinical trial programme to evaluate the safety and efficacy of dolutegravir (Tivicay) and rilpivirine (Edurant) as maintenance therapy for adult patients with HIV. [More]
NTNU researchers find link between sleep disorders and psychiatric problems in young children

NTNU researchers find link between sleep disorders and psychiatric problems in young children

Toddlers who take a long time to fall asleep or wake up many times during the night have put many a desperate mom and dad to the test. Tired parents are often told that night waking is part of toddlerhood, and that it will soon pass on its own, but this is not the case for everyone. [More]
Night shift workers classified as alert insomniacs have highest level of impairment in work productivity

Night shift workers classified as alert insomniacs have highest level of impairment in work productivity

A new study of night shift workers suggests that overnight occupational and cognitive impairment is more strongly correlated to insomnia than it is to sleepiness. [More]
Sofosbuvir in combination with ribavirin/peginterferon achieves highest SVR rates in GT-3 HCV patients

Sofosbuvir in combination with ribavirin/peginterferon achieves highest SVR rates in GT-3 HCV patients

Results presented today at The International Liver Congress 2015 demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date. [More]
AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

AbbVie has announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV). [More]
Neuroscientists identify novel brain circuitry that increases anxiety during nicotine withdrawal

Neuroscientists identify novel brain circuitry that increases anxiety during nicotine withdrawal

In a promising breakthrough for smokers who are trying to quit, neuroscientists at the University of Massachusetts Medical School and The Scripps Research Institute have identified circuitry in the brain responsible for the increased anxiety commonly experienced during withdrawal from nicotine addiction. [More]
Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith Laboratories, Inc. presented data from a 52-week, open-label extension study (PREVAIL OLE) showing that Qudexy XR (topiramate) extended-release capsules offered a long-term adjunctive treatment option with a favorable tolerability profile for a high proportion of patients with refractory partial-onset seizures (POS). [More]
Tonix expert examines ways to improve sleep problems and provide relief to people with PTSD

Tonix expert examines ways to improve sleep problems and provide relief to people with PTSD

Sleep problems—a common condition among military personnel—may increase the risk of developing post-traumatic stress disorder (PTSD) and other mental health conditions. So concludes a team of researchers at the RAND Corporation, whose study—published on RAND's website—was recently described in national media outlets. [More]
New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, today announced that clinical data for simeprevir, its NS3/4A protease inhibitor for the treatment of hepatitis C virus (HCV) infection, will be presented at The International Liver Congress 2015 of the European Association for the Study of the Liver taking place in Vienna from April 22-26. [More]
Symptoms of depression, insomnia are risk factors for frequent nightmares, study suggests

Symptoms of depression, insomnia are risk factors for frequent nightmares, study suggests

A new study suggests that symptoms of depression and insomnia are the strongest predictors of having frequent nightmares. [More]
Exercise and physical activity improve lung cancer outcomes

Exercise and physical activity improve lung cancer outcomes

Exercise and physical activity should be considered as therapeutic options for lung cancer as they have been shown to reduce symptoms, increase exercise tolerance, improve quality of life, and potentially reduce length of hospital stay and complications following surgery for lung cancer. [More]
Screening people at risk of PTSD can help prevent further cases going unnoticed

Screening people at risk of PTSD can help prevent further cases going unnoticed

When people have repeated non-specific health problems, it could be related to previous exposure to traumatic events. GPs may be seeing more patients with post-traumatic stress disorder (PTSD) as military personnel return from overseas deployments. [More]
New Johns Hopkins mobile app educates care providers on improving sleep, overall health of patients

New Johns Hopkins mobile app educates care providers on improving sleep, overall health of patients

Experts from the Johns Hopkins Center for Sleep hope to help patients get a better night’s sleep by providing health care staff members with a basic educational tool on their smartphones. [More]
Roseroot extract may be beneficial for treating major depressive disorder

Roseroot extract may be beneficial for treating major depressive disorder

Rhodiola rosea (R. rosea), or roseroot, may be a beneficial treatment option for major depressive disorder (MDD), according to results of a study in the journal Phytomedicine led by Jun J. Mao, MD, MSCE, associate professor of Family Medicine, Community Health and Epidemiology and colleagues at the Perelman School of Medicine of University of Pennsylvania. [More]
Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII. [More]
Egalet announces net revenues of $1.9 million for 2014

Egalet announces net revenues of $1.9 million for 2014

Egalet Corporation today reported financial results for the year ended December 31, 2014. [More]
AASM publishes new quality measures for common sleep disorders

AASM publishes new quality measures for common sleep disorders

Today the American Academy of Sleep Medicine published new quality measures for five common sleep disorders, which represents a landmark achievement in the promotion of high quality, patient-centered care in the medical subspecialty of sleep medicine. [More]
Advertisement
Advertisement